These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 1071663)

  • 1. Vasopressin and malignant deoxycorticosterone hypertension in rats.
    Möhring J; Möhring B; Petri M; Haack D
    Clin Sci Mol Med Suppl; 1976 Dec; 3():45s-48s. PubMed ID: 1071663
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Is vasopressin involved in the pathogenesis of malignant desoxycorticosterone hypertension in rats?
    Möhring J; Möhring B; Petri M; Haack D
    Lancet; 1976 Jan; 1(7952):170-3. PubMed ID: 54684
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vasopressor role of ADH in the pathogenesis of malignant DOC hypertension.
    Möhring J; Möhring B; Petri M; Haack D
    Am J Physiol; 1977 Mar; 232(3):F260-9. PubMed ID: 842673
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Contribution of vasopressin to the maintenance of blood pressure in deoxycorticosterone-salt induced malignant hypertension in spontaneously hypertensive rats.
    Hiwatari M; Abrahams JM; Saito T; Johnston CI
    Clin Sci (Lond); 1986 Feb; 70(2):191-8. PubMed ID: 3956109
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasma vasopressin concentrations and effects of vasopressin antiserum on blood pressure in rats with malignant two-kidney Goldblatt hypertension.
    Möhring J; Möhring B; Petri M; Haack D
    Circ Res; 1978 Jan; 42(1):17-22. PubMed ID: 618598
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Changes of vasopressin in hypertension: Cause or effect?
    Padfield PL; Brown JJ; Lever AF; Morton JJ; Robertson JI
    Lancet; 1976 Jun; 1(7972):1255-7. PubMed ID: 73691
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alpha and beta adrenoceptor blockade in normotensive and deoxycorticosterone (DOC)-hypertensive rats; plasma vasopressin and vasopressin pressor effect.
    Burnier M; Biollaz J; Brunner DB; Gavras H; Brunner HR
    J Pharmacol Exp Ther; 1983 Jan; 224(1):222-7. PubMed ID: 6129318
    [No Abstract]   [Full Text] [Related]  

  • 8. Osmotic stimulation in DOC-salt hypertension: vasopressin and blood pressure.
    Crofton JT; Share L; Brooks DP
    J Hypertens; 1986 Jun; 4(3):307-12. PubMed ID: 3734447
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Contributions of vasopressin and other pressor systems to DOC-salt hypertension in rats.
    Mento PF; Wang HH; Sawyer WH
    Proc Soc Exp Biol Med; 1984 Jan; 175(1):58-63. PubMed ID: 6694969
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of neurohormonal changes following the production of the benign and malignant phases of two-kidney, two-clip Goldblatt hypertension.
    Suzuki H; Saruta T; Ferrario CM; Brosnihan KB
    Jpn Heart J; 1987 May; 28(3):413-26. PubMed ID: 2887673
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vascular lesions and angiotensin in malignant hypertension in the absence of vasopressin.
    Woods RL; Abrahams JM; Kincaid-Smith P; Johnston CI
    Clin Exp Pharmacol Physiol; 1982; 9(3):297-301. PubMed ID: 6754178
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neurohypophyseal vasopressor principle: vasopressor hormone as well as antidiuretic hormone?
    Möhring J
    Klin Wochenschr; 1978; 56 Suppl 1():71-9. PubMed ID: 732254
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased renal excretion of arginine-vasopressin during mild hydropenia in young men with mild essential benign hypertension.
    Khokhar AM; Slater JD
    Clin Sci Mol Med Suppl; 1976 Dec; 3():691s-694s. PubMed ID: 1071711
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evidence against a vasopressor role of ADH in malignant DOC-salt hypertension.
    Filep J; Frölich JC; Fejes-Toth G
    Clin Exp Hypertens A; 1985; 7(10):1457-70. PubMed ID: 3841034
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of AVP in malignant DOC-salt hypertension: studies using vascular and antidiuretic antagonists.
    Filep J; Frölich JC; Földes-Filep E
    Am J Physiol; 1987 Nov; 253(5 Pt 2):F952-8. PubMed ID: 3688242
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The importance of vasopressin in the mechanism maintaining hypertension in the rat.
    Yazaki Y; Ohuchi Y; Ashida T; Saito T
    Jpn Circ J; 1981 Sep; 45(9):1116-20. PubMed ID: 7300021
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sex difference in the development of deoxycorticosterone-salt hypertension in the rat.
    Ouchi Y; Share L; Crofton JT; Iitake K; Brooks DP
    Hypertension; 1987 Feb; 9(2):172-7. PubMed ID: 3818014
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hemorrhage in DOC-salt hypertensive rats: plasma and platelet vasopressin.
    Crofton JT; Share L; Brooks DP
    Am J Physiol; 1985 Dec; 249(6 Pt 2):R726-31. PubMed ID: 4073293
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasma immunoreactive endothelin-1 in experimental malignant hypertension.
    Kohno M; Murakawa K; Horio T; Yokokawa K; Yasunari K; Fukui T; Takeda T
    Hypertension; 1991 Jul; 18(1):93-100. PubMed ID: 1860718
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of acute vasopressin infusion on blood pressure and plasma angiotensin II in normotensive and DOCA-salt hypertensive rats.
    Morton JJ; Garcia del Rio C; Hughes MJ
    Clin Sci (Lond); 1982 Feb; 62(2):143-9. PubMed ID: 7053914
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.